ArticleEndocrine connections2026
Digital vs conventional glycemic monitoring in rare endocrine cancers: comparison of effectiveness during chemotherapy.
Article in Endocrine connections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diabetes and cancer: glucose control impact on survival and tumor outcomes.Reviews in endocrine & metabolic disorders · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Chemotherapy regimens can induce severe hyperglycemia, which may be underestimated using conventional point-of-care blood glucose (POC-G) measurement techniques. Real-time continuous glucose monitoring (rtCGM) systems may offer a more accurate assessment of glucose metabolism. In this study, we compared blood glucose monitoring using POC-G and rtCGM in patients with rare endocrine cancers caused by chemotherapy and steroid medication. Methods: In this single-center observational study, we analyzed data from 76 hospitalized patients with pancreatic neuroendocrine tumors (n = 48) or adrenocortical carcinoma (n = 28) undergoing chemotherapy. Patients were monitored using either POC-G (n = 38) or rtCGM (n = 38). Glycemic metrics included time in range (TIR), prevalence of steroid-induced hyperglycemia (SIH), and HbA1c. Results: Using POC-G, TIR was 23.6 ± 0.9 h/day in patients without diabetes (NoD) and 20.0 ± 4.2 h/day in patients with diabetes undergoing chemotherapy (mean: five cycles). However, when rtCGM was used, drastic changes in TIR were documented under the same regimen. The mean TIR decreased from 21.7 h/day in patients with NoD to 14.6 h/day in patients with diabetes (P < 0.01). Similarly, the overall incidence of SIH was 30% using conventional POC monitoring, but this figure rose to 79% using rtCGM. During rtCGM use, HbA1c decreased by 0.3% over the course of the chemotherapy cycles, whereas during POC-G use, HbA1c increased by 0.2% (P < 0.01). Conclusion: We demonstrated a previously underestimated frequency of hyperglycemia and SIH in patients undergoing chemotherapy by using rtCGM. The use of rtCGM enabled more detailed recognition of dysglycemia and may improve glucose metabolism during and after chemotherapy regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.